ACE2 and inflammatory bowel disease: Studies have been conducted to evaluate the risk factors in IBD patients who were infected with SARS-CoV-2, studies that focused on the regulation of ACE-2 and TMPRSS2 in the ileum and colon and on monitoring the effects of drugs used for IBD regarding the change in the expression of these two proteins and the increase in the vulnerability of the disease.